Olanzapine/fluoxetine combination for treatment-resistant depression: Efficacy and clinical utility

Expert Review of Neurotherapeutics

Volumn 8, Issue 9, 2008, Pages 1299-1306

  Dodd, Seetal ^a   Berk, Michael ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

Antidepressant; Atypical antipsychotic; Olanzapine fluoxetine combination; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORFLUOXETINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIPRASIDONE;

ANXIETY; ASTHENIA; BIPOLAR DEPRESSION; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; METABOLIC SYNDROME X; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PERSONALITY DISORDER; QT INTERVAL; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; WEIGHT GAIN; XEROSTOMIA;

BENZODIAZEPINES; DEPRESSION; DRUG COMBINATIONS; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 51149117395     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.9.1299     Document Type: Review

References (63)

1. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006).
2. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int. Clin. Psychopharmacol. 9(Suppl. 2), 5-10 (1994).
3. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry 63(2), 95-103 (2002).
4. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J. Clin. Psychiatry 67(Suppl. 6), 16-22 (2006).
5. Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect. Disord. 89(1-3), 1-11 (2005).
6. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress. Anxiety 4(4), 169-181 (1996).
7. Brent D, Emslie G, Clarke G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299(8), 901-913 (2008).
8. Brent DA, Holder D, Kolko D et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch. Gen. Psychiatry 54(9), 877-885 (1997).
9. Lau MA. New developments in psychosocial interventions for adults with unipolar depression. Curr. Opin. Psychiatry 21(1), 30-36 (2008).
10. Martinez J, Garakani A, Marcus S et al. A randomized, double-blind, placebo controlled trial of quetiapine combined with fluoxetine in major depressive disorder. Presented at: 59th Institute of Psychiatric Services Conference. LA, USA, 11-14 October 2007.
11. McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24(7), 487-494 (2007).
12. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 843-853 (2007).
13. El-Khalili N, Joyce M, Atkinson S et al. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. Presented at: American Psychiatric Association Annual Meeting. DC, USA, 3-8 May 2008.
14. Beasley CM Jr, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14(2), 111-123 (1996).
15. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158(1), 131-134 (2001). • Although small, this is still an important acute-phase clinical trial of the olanzapine/fluoxetine combination (OFC).
16. Beasley CM Jr, Dornseif BE, Bosomworth JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 303(6804), 685-692 (1991).
17. Weisler R, Joyce M, McGill L et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study. Presented at: American Psychiatric Association Annual Meeting. DC, USA, 3-8 May 2008.
18. Datto C, Lam RW, Lepola U et al. Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD). Presented at: American Psychiatric Association Annual Meeting. DC, USA, 3-8 May 2008.
19. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J. Affect. Disord. 43(2), 95-103 (1997).
20. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry 68(7), 1071-1077 (2007).
21. Gharabawi G, Canuso C, Pandina G et al. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int. J. Neuropsychopharmacology 9(Suppl. 1), S236 (2006).
22. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry 60(4), 256-259 (1999).
23. Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci. 4(2), E11 (2002).
24. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37(3), 177-193 (1999).
25. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85(1), 11-28 (2000).
26. Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr. Drug Metab. 7(2), 127-133 (2006).
27. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2), 87-96 (1996).
28. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.) 124(1-2), 87-94 (1996).
29. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50(5), 345-350 (2001).
30. DeVane CL. Differential pharmacology of newer antidepressants. J. Clin. Psychiatry 59(Suppl. 20), 85-93 (1998).
31. Zhang W, Perry KW, Wong DT et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23(3), 250-262 (2000).
32. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl.) 185(3), 274-281 (2006).
33. Moller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur. Arch. Psychiatry Clin. Neurosci. 255(3), 190-201 (2005). •• Insightful review of the pharmacology of atypical antipsychotics.
34. Jensen NH, Rodriguiz RM, Caron MG et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1α agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33(10), 2303-2312 (2008).
35. Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24(4), 365-373 (2004).
36. Brown EB, McElroy SL, Keck PE Jr et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry 67(7), 1025-1033 (2006).
37. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60(11), 1079-1088 (2003).
38. Corya SA, Perlis RH, Keck PE Jr et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J. Clin. Psychiatry 67(5), 798-806 (2006).
39. Dube S, Tollefson GD, Thase ME et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 9(6), 618-627 (2007).
40. Shi L, Namjoshi MA, Swindle R et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin. Ther. 26(1), 125-134 (2004).
41. Keck PE Jr, Corya SA, Altshuler LL et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J. Clin. Psychiatry 66(5), 611-616 (2005).
42. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry 65(7), 903-907 (2004).
43. Dube S, Andersen SW, Paul S et al. Metanalysis of olanzapine/fluoxetine use in treatment-resistant depression. Presented at: XXIII CINP Congress - Collegium Internationale Neuro-Psychopharmacologicum (CINP). QC, Canada, 23-27 June 2002.
44. Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66(10), 1289-1297 (2005). • Important acute-phase clinical trial of OFC.
45. Corya SA, Williamson D, Sanger TM et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23(6), 364-372 (2006). • Important acute-phase clinical trial of OFC.
46. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 68(2), 224-236 (2007). • Important acute-phase clinical trial of OFC.
47. Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry 64(11), 1349-1356 (2003). • Important maintenance-phase trial of OFC.
48. Girgis RR, Duggal HS, Douaihy AB. Respiratory depression from Symbyax overdose and binge drinking. Gen. Hosp. Psychiatry 28(3), 255-256 (2006).
49. Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J. Affect. Disord. 103(1-3), 181-186 (2007).
50. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J. Clin. Psychopharmacol. 27(5), 451-458 (2007).
51. Bull SA, Hu XH, Hunkeler EM et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 288(11), 1403-1409 (2002).
52. Moore D. Dan Moore, President and CEO, Cyberonics, Inc. Presented at: Lazard Capital Markets, Fourth Annual Healthcare Conference. NY, USA, 27 November 2007.
53. Crown WH, Finkelstein S, Berndt ER et al. The impact of treatment-resistant depression on health care utilization and costs. J. Clin. Psychiatry 63(11), 963-971 (2002).
54. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32(4), 675-692 (2008).
55. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 19(12), 5034-5043 (1999).
56. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 21, 1-26 (2008).
57. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 29, 346-351 (2008).
58. Pasco JA, Jacka FN, Williams LJ et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J. Affect. Disord. 107(1-3), 221-225 (2008).
59. Berk M, Dodd S, Kauer-Sant'anna M et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. (434), 41-49 (2007).
60. Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J, Clin. Psychiatry 65(Suppl. 17), 29-33 (2004).
61. US FDA. Aripiprazole prescribing information (2008) www.fda.gov/MedWatch/ safety/2008/Feb_PI/Abilify_PI.pdf
62. Food and Drug Administration. Approval Order: VNS Therapy System (P970003/S50) (2005) www.fda.gov/ohrms/dockets/dockets/05m0283/05m-0283-aav0001- 02-Approval-Order-vol1.pdf
63. Food and Drug Administration. Olanzapine/Fluoxetine (marketed as Symbyax) Information (2008) www.fda.gov/cder/drug/infopage/olanzapine_fluoxetine/ default.htm